Screener
Gilead Sciences GILD Symtuza - Revenue share — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | Three Months Ended June 30, 2026 / U.S. | Three Months Ended June 30, 2026 / Europe | Three Months Ended June 30, 2026 / Rest of World | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / U.S. | Three Months Ended June 30, 2025 / Europe | Three Months Ended June 30, 2025 / Rest of World | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|---|---|
| Descovy | 921 | 23 | 23 | 967 | 601 | 24 | 28 | 653 |
| Genvoya | 236 | 37 | 16 | 289 | 322 | 40 | 16 | 377 |
| Odefsey | 171 | 58 | 10 | 239 | 221 | 66 | 11 | 298 |
| Symtuza - Revenue share(1) | 105 | 30 | 3 | 138 | 88 | 33 | 3 | 124 |
| Yeztugo | 223 | — | 9 | 232 | 15 | — | — | 15 |
| Other HIV(2) | 23 | 24 | 10 | 56 | 50 | 33 | 9 | 92 |
| Total HIV | 4,659 | 640 | 393 | 5,693 | 4,096 | 624 | 368 | 5,088 |
| Liver Disease |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's symtuza - revenue share — total revenues?
- Gilead Sciences (GILD) reported symtuza - revenue share — total revenues of $138M in Q2 2026.
- How has Gilead Sciences's symtuza - revenue share — total revenues changed year-over-year?
- Gilead Sciences's symtuza - revenue share — total revenues increased by 11.3% year-over-year, from $124M to $138M.
- What is the long-term trend for Gilead Sciences's symtuza - revenue share — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's symtuza - revenue share — total revenues has grown at a -2.3% compound annual growth rate (CAGR), from $530M to $495M.
- What does symtuza - revenue share — total revenues mean?
- This metric represents the total revenue generated from the company's profit-sharing arrangement or royalty interest in the specific HIV therapeutic product known as Symtuza. It reflects the financial contribution of this specific co-formulated treatment to the company's overall top-line performance within its broader infectious disease portfolio. Monitoring this figure helps assess the market performance and lifecycle maturity of this specific asset within the competitive HIV treatment landscape.
Ask your AI about Gilead Sciences's symtuza - revenue share — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude